Treatment
Psilocybin clinical trials
We’re tracking 104 recruiting studies that include Psilocybin, each written for real people, not researchers, below.
Recruiting studies
- NCT06919640Enrolling by invitationPhase 1
Psilocybin and brain implant study
This trial tests whether psilocybin (the active ingredient in magic mushrooms) affects brain activity in people who already have a brain-sensing device implanted. It may help researchers understand how psilocybin works in the brain.
San Francisco, CaliforniaAges 21–75 - NCT06902974RecruitingPhase 2
Psilocybin therapy for PTSD from sexual assault
This trial tests whether psilocybin, a psychedelic drug given in a supportive therapy setting, can help women heal from post-traumatic stress disorder (PTSD) caused by a sexual assault that happened 6 or more months ago. You'll receive the drug during supervised sessions and attend therapy visits to see if it reduces your PTSD symptoms.
Rockville, MarylandAges 18 years+ - NCT06899165RecruitingPhase 2
Psilocybin therapy for inherited trauma
This trial tests whether psilocybin (a psychedelic substance) combined with therapy can help adult children of genocide survivors who experience symptoms of trauma, depression, or anxiety. The goal is to see if this approach can reduce the emotional impact of intergenerational trauma.
New York, New YorkAges 18 years+ - NCT06899594RecruitingEarly Phase 1
Psilocybin for quitting methamphetamine
This trial tests whether psilocybin (a psychedelic medicine) can help people quit methamphetamine. You'll receive counseling before, during, and after the drug session, and your progress will be followed for several months.
Shreveport, LouisianaAges 25–65 - NCT06818994RecruitingPhase 1
Psilocybin therapy for low mood in advanced cancer
This trial tests if a medicine called psilocybin, given with talk therapy, can safely help people with advanced cancer who feel very demoralized. Demoralization is a deep sense of hopelessness or loss of meaning. The goal is to see if this treatment can improve your emotional well-being.
Kingston, OntarioAges 18–70 - NCT06814522RecruitingPhase 1/Phase 2
Psilocybin-assisted therapy for physician burnout
This study tests whether a psychedelic drug called psilocybin, combined with talk therapy, can help reduce burnout in doctors. It may help improve well-being and job satisfaction.
San Diego, CaliforniaAges 21–70 - NCT06796062RecruitingPhase 2
Psilocybin for opioid use disorder
This study tests whether psilocybin can help people who want to stop using opioids and are already in treatment. Eligible participants receive a single dose of psilocybin in a supervised setting and are followed to see if it reduces opioid use.
Albuquerque, New MexicoAges 18–65 - NCT06801041RecruitingPhase 2
Psilocybin therapy for anxiety or depression in cancer survivors
This trial tests if a single dose of psilocybin, given with therapy, can help cancer survivors who struggle with anxiety or depression. You would travel to MD Anderson for treatment and follow-up, and must stop certain medications beforehand.
Houston, TexasAges 18 years+ - NCT06786325RecruitingPhase 2
Psilocybin treatment study for opioid use disorder
This trial tests whether psilocybin can help people recovering from opioid use disorder while living at a residential treatment center. If you are already taking buprenorphine/naloxone (Suboxone), methadone, or have received Sublocade, this study may be an option for you.
Philadelphia, PennsylvaniaAges 18–60 - NCT06782724RecruitingPhase 2
Psilocybin therapy for distress in advanced illness
This trial tests whether a single dose of psilocybin (a psychedelic medicine) can help reduce depression and distress in people with advanced lung disease, ALS, multiple sclerosis, or Parkinson's. You would receive preparation, the drug, and follow-up support in a safe, supervised setting.
PragueAges 18 years+ - NCT06724289RecruitingEarly Phase 1
Psilocybin for prolonged grief
This trial tests if a single dose of psilocybin (a psychedelic drug) can help people with prolonged grief disorder. You'll receive counseling and be observed in a safe setting.
Charlottesville, VirginiaAges 18–65 - NCT06706232RecruitingPhase 2
Psilocybin for Depression and Suicidal Thoughts in Bipolar II
This trial tests if two doses of psilocybin, given under medical supervision, are safe and acceptable for people with Bipolar II disorder who have mild to moderate depression and certain suicidal thoughts. The goal is to see if it may help improve mood and reduce suicidal thinking.
Houston, TexasAges 25–70 - NCT06660381RecruitingPhase 1
Psilocybin therapy for cannabis use disorder
This study tests if psilocybin (a substance that can change how you think and feel) can help people reduce or stop using cannabis. You will receive support and be monitored closely throughout the trial.
Baltimore, MarylandAges 18 years+ - NCT06656702RecruitingEarly Phase 1
Psilocybin for depression in amyotrophic lateral sclerosis
This trial tests whether psilocybin, a psychedelic drug, can safely help with depression in people with ALS. It also looks at how the drug affects your symptoms and quality of life over six months.
Baltimore, MarylandAges 18 years+ - NCT06626139RecruitingPhase 2
Psilocybin study for healthy volunteers
This trial tests how the setting and context affect the experience of psilocybin, a psychedelic drug. It aims to understand how the environment influences the effects in healthy adults.
San Francisco, CaliforniaAges 21–70 - NCT06615908RecruitingPhase 1
Psilocybin therapy for lingering concussion symptoms
This study tests whether a single dose of psilocybin, given with therapist support, can reduce long-lasting symptoms after a concussion. If your symptoms have continued for months, you may be eligible.
Calgary, AlbertaAges 18–65 - NCT06518720RecruitingPhase 2
Psilocybin for Chronic Nerve Pain and Depression
This trial tests whether psilocybin (a psychedelic medication) can help people who have both chronic nerve pain and depression that hasn't responded to standard treatments. The goal is to see if it can reduce pain and improve mood.
Toronto, OntarioAges 18–65 - NCT06512194RecruitingPhase 2
Psilocybin for depression study
This trial tests whether psilocybin can help people with major depression who are currently having a depressive episode. It aims to understand how the treatment works and if it is safe and effective.
Edwards, ColoradoAges 18–70 - NCT06464367RecruitingEarly Phase 1
Psilocybin study for migraine and healthy volunteers
This study looks at how psilocybin affects the brain in people with migraines and in healthy volunteers. The goal is to understand why it may help with headache disorders.
West Haven, ConnecticutAges 21–70 - NCT06442423RecruitingPhase 1
Psilocybin study for people with psychiatric symptoms
This trial tests if psilocybin, a substance found in certain mushrooms, can help people with various mental health symptoms that affect daily life. You would take a single dose in a supervised setting and be monitored for changes in your mood and well-being.
New Haven, ConnecticutAges 18 years+ - NCT06455293RecruitingPhase 2
Psilocybin therapy for depression in Parkinson's disease
This study tests whether psilocybin, a substance found in certain mushrooms, can help improve depression in people with Parkinson's disease. If you have Parkinson's and are feeling depressed, this treatment may offer a new option.
San Francisco, CaliforniaAges 40–80 - NCT06368492Recruiting
Psilocybin for fibromyalgia pain
This trial tests whether psilocybin, a substance found in certain mushrooms, can help reduce pain in people with fibromyalgia. You would receive the drug and be monitored closely to see if it improves your pain levels.
Maastricht, LimburgAges 18–65 - NCT06430541RecruitingPhase 1
Psilocybin therapy for fear of cancer recurrence
This trial tests if psilocybin-assisted therapy can help reduce the intense worry that cancer might come back. It is for people who have finished their main treatments for early-stage breast cancer or advanced ovarian cancer.
Aurora, ColoradoAges 21 years+ - NCT06405607RecruitingPhase 2
Psilocybin vs Ketamine for Alcohol Use Disorder Trial
This trial tests two psychedelic-assisted therapies, psilocybin and ketamine, to see which works better for reducing heavy drinking in people with alcohol use disorder (AUD). You'll receive either drug along with counseling, and the study monitors safety closely.
Iowa City, IowaAges 21–65
Common questions
- Are there clinical trials studying Psilocybin?
- Yes. Clin2 currently lists 104 recruiting studies that include Psilocybin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Psilocybin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Psilocybin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Psilocybin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.